Bristol-myers Squibb Compnay

The Dupont Merck Pharmaceutical Company

E.i. Dupont De Nemours and Company

Dupont Pharmaceuticals Company

Bristol-myers Squibb Pharma Company

Dupont Pharmaceuticals, Inc.

Bristol-myers Squibb Pharma Corporation

Du Pont Merck Pharmaceutical

Douglas G. Batt

Douglas G Batt

Qingjie Liu

Soo Sung Ko

William John Pitts

Percy H Carter

Joseph Anthony Tino

Scott Hunter Watterson

George V Delucca

Michael J Orwat

Robert J Cherney

John V Duncia

Michael G Yang

Daniel S Gardner

Dean A Wacker

Donald J Pinto

John E Macor

T G Murali Dhar

Saleem Ahmad

John Wityak

Prabhakar Kondaji Jadhav

Satheesh Kesavan Nair

David Marcoux

Richard Eric Olson

Shaker Ahmed Mousa

Chu-Biao Xue

Chunjian Liu

James Russell Pruitt

Gary Avonn Cain

Andrew J Tebben

Michael A Poss

Amit Kumar

Jingwu Duan

Joseph B Santella

Stephen T Wrobleski

David S Weinstein

Steven H Spergel

John S Tokarski

James M Lin

Hai-Yun Xiao

Rajeev S Bhide

Matthew Ernst Voss

Scott Hunter

Kurt Zimmermann

Harold A Mastalerz

Zili Xiao

Ashok Vinayak Purandare

Yeheng Zhu

Khehyong Ngu

Ronald L Magolda

Hua Gong

Anurag S Srivastava

Qing Shi

Myra Beaudoin Bertrand

Joseph J Petraitis

Carl Henry Behrens

Charles Malcolm Langevine

Irina Cipora Jacobson

Munir A Hussain

Tarun Kumar Maishal

Michael A Galella

George V De Lucca

Lyndon A M Cornelius

Carolyn A Weigelt

William Galbraith

Thais Motria Sielecki-Dzurdz

Ryan M Moslin

Shuqun Lin

Zheming Ruan

Arnold J Repta

Weiwei Guo

Guifen Zhang

Paul M Simon

William Frank Degrado

Gregory D Brown

Feng Qiu

Richard S Greenberg

Lan-Ying Qin

Walter Lewis Johnson

Susan R Sherk

Yanlei Zhang

James Neels

Tg Murali Dhar

Richard R Harris

Joanne Marie Smallheer

Rui-Qin Liu

Stephen W Wright

Chunijan Liu

Lyndon AM Cornelius

Charles M Langevine

Disclosed are compounds of Formula (I): or a salt thereof, wherein Q, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Carbazole derivatives

There are described RORmodulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORactivity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORactivity, for example, autoimmune and/or inflammatory disorders. 

Tricyclic sulfones as RORmodulators

Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: Ris F, Cl, &#x2014;CN, or &#x2014;CH; Ris Cl or &#x2014;CH; Ris &#x2014;C(CH)OH or &#x2014;CHCHOH; Ris H or &#x2014;CH; each Ris independently F, Cl, &#x2014;CH, and/or &#x2014;OCH; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

There are described ROR&#x3b3; modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders.

Tricyclic sulfones as ROR gamma modulators

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein Q, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 

Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Qis: (i) Cl, Br, I, &#x2014;CN, &#x2014;CH, or &#x2014;CF; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Rand zero to 1 R; and R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases. 

Bicyclic heteroaryl amine compounds

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN&#x3b1;, by acting on Tyk-2 to cause signal transduction inhibition.

Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses

There are described ROR&#x3b3; modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders.

Tricyclic sulfones as ROR&#x3b3; modulators

Disclosed are compounds of Formula (I); and salts thereof, wherein: Formula (II); Q is: Ris &#x2014;C(CH)2OH, &#x2014;NHC(=0)C(CH), &#x2014;N(CH3)2, or &#x2014;CHR; Ris CI or &#x2014;CH; Ris H, F, or &#x2014;CH; Ris H or &#x2014;CH; Ris H, F, CI, or &#x2014;OCH3 Ris H or F; and Rd is &#x2014;OH, &#x2014;OCH3, &#x2014;NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 

Carbazole carboxamide compounds

The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof The Formula (I) compounds inhibit tyrosine kinase activity of Jak2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Carbazole and carboline kinase inhibitors

The present application describes modulators of MCP-1 or CCR-2 of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, W, W, Y, Z, R, R, R' and R, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed. 

Chromene modulators of chemokine receptor activity

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, formula (I) are useful as kinase modulators, including Btk modulation. 

Carboline carboxamide compounds useful as kinase inhibitors

Growing community of inventors

Wilmington, DE, United States of America

Douglas G Batt